Relugolix0 vendors competing
No vendor pricing available for this peptide yet.
Research details
Relugolix — research data
Regulatory statusFDA-approved (Orgovyx)
NCAA D1Banned
Overview
About Relugolix
Mechanism of action
Oral GnRH receptor antagonist; rapid testosterone suppression reversible on discontinuation
Safety profile
Hot flashes, cardiovascular events, bone loss · Approved for prostate cancer; oral delivery; hot flashes; well-characterized
Related pages